Introduction
Living with cold agglutinin disease (CAD) can be challenging, especially for patients who experience ongoing anemia, fatigue, weakness, shortness of breath, and other symptoms caused by the destruction of red blood cells. Because CAD is a rare autoimmune disorder, treatment options have historically been limited, leaving many patients dependent on supportive care and blood transfusions to manage their condition.
Enjaymo is a prescription biologic medication specifically designed to address hemolysis associated with cold agglutinin disease. By targeting a key protein involved in the immune process that destroys red blood cells, Enjaymo helps reduce hemolysis and decrease the need for blood transfusions in eligible adults with CAD.
As a specialty biologic therapy administered by intravenous infusion, Enjaymo can be extremely expensive without adequate insurance coverage or financial assistance. Many patients searching for the Enjaymo patient assistance program are looking for ways to make treatment more affordable while maintaining access to prescribed therapy.
Prescription Hope offers medication access to patients needing affordable brand-name medications.
What Is the Enjaymo Patient Assistance Program?
Understanding Enjaymo Prescription Assistance
People looking for help paying for Enjaymo have most likely found plenty of solutions. However, some solutions may not fit your situation.
When a patient has inadequate insurance coverage, lacks meaningful savings from discount cards or coupons, or falls into government assistance gaps, they can feel lost and unsure how to move forward.
Pharmaceutical manufacturers understand their brand-name medications may be too expensive for patients who must pay out-of-pocket costs.
To help alleviate the financial burden, manufacturers launch patient assistance programs to provide patients access to affordable medications.
However, due to the strict requirements of these programs, patients often feel overwhelmed with the application process. Navigating it on their own can mean stress, frustrations, and unnecessary application denials.
Prescription Hope can help.
How Expert Advocates Help Make Enjaymo More Affordable
Personalized Medication Assistance
Prescription Hope is a medication access advocacy organization. We provide patient support services for those looking to save on their monthly medication costs.
Our medication advocate support handles your patient assistance program journey from start to finish. We complete forms, handle document and signature collection, work with your healthcare provider and the manufacturer, and advocate on your behalf when issues arise.
Ongoing Patient Support
Not only that, but our team of patient advocates continues to help you with your rare disease medication support services. Our long-term medication assistance means we manage required administrative tasks, such as refill scheduling, document updates, yearly renewals, and more.
Navigating Rare Disease Treatment Costs
Those looking for prescription access solutions are often used to seeing expensive costs associated with their medications and healthcare services.
Prescription Hope is different. We are not an insurance company, manufacturer, discount card, or coupon. We are a comprehensive medication access service with a low monthly rate of $70.00 per month, per medication.
Our service rate never includes add-ons or varying service packages. You never pay medication costs or variable pricing.
And if we cannot help you save, then you pay nothing!
Enjaymo Price Comparison
vs
Estimated Retail Price*
30-Day Supply
Prescription Hope Price
Per Month, NO Matter The Retail Price
*Source: Drugs.com
Enjaymo Patient Assistance Eligibility
General Eligibility Requirements
Prescription assistance requirements set by patient assistance programs can vary, depending on the program’s criteria. However, qualification standards typically fall into several categories:
Income: All programs maintain their own income threshold standards.
Insurance: All programs also maintain their own insurance coverage status criteria.
Prescription: Qualified applicants must have a valid prescription for their intended medication.
U.S. Residency: All patients must be legal U.S. residents to qualify.
Simple Enrollment With Expert Support
Getting Started With Enrollment
If you’re ready to enroll in Enjaymo assistance and want our patient advocates to handle your Enjaymo application process, then enrolling with Prescription Hope only takes 6 simple steps:
- Submit Information: Prescription Hope’s enrollment form only takes a few minutes to complete.
- Advocate Contact: Our patient advocates will reach out within 1-2 business days after receiving your completed form.
- Document Collection: Applications require extensive documentation. We collect it on your behalf.
- Provider Coordination: Every application also requires healthcare provider signatures. Our patient advocates communicate with your healthcare providers and secure those needed signatures.
- Program Submission: Once your application packet is complete, we submit it to the manufacturer and coordinate with them throughout the processing stage.
- Medication Delivery: Following approval, medication ships directly to the patient’s door or doctor’s office. Medication typically ships within 2 weeks of approval.
Prescription Hope is not a pharmacy or manufacturer and therefore does not handle medications at any time.
Understanding Enjaymo
How Enjaymo Works
Enjaymo is a monoclonal antibody that targets C1s, a protein involved in activation of the classical complement pathway. In patients with cold agglutinin disease, the immune system mistakenly produces antibodies that attach to red blood cells and trigger complement-mediated destruction, a process known as hemolysis.
When hemolysis occurs, red blood cells are broken down faster than the body can replace them, leading to anemia and related symptoms. By inhibiting C1s, Enjaymo blocks a critical step in the classical complement pathway that contributes to red blood cell destruction.
This targeted mechanism helps reduce complement-mediated hemolysis, improve hemoglobin levels, and decrease the need for blood transfusions. Rather than broadly suppressing the immune system, Enjaymo focuses on a specific component of the complement pathway involved in CAD.
What Conditions Does Enjaymo Treat?
Enjaymo is FDA-approved to decrease the need for red blood cell transfusions due to hemolysis in adults with cold agglutinin disease (CAD).
Cold agglutinin disease is a rare autoimmune blood disorder in which the body’s immune system mistakenly attacks red blood cells, particularly during exposure to cold temperatures. The resulting destruction of red blood cells can cause chronic hemolytic anemia and symptoms such as fatigue, weakness, dizziness, shortness of breath, and reduced exercise tolerance.
Healthcare providers may prescribe Enjaymo for adults with CAD who experience ongoing hemolysis, anemia-related symptoms, or a need for blood transfusions. The medication was the first FDA-approved therapy specifically indicated for cold agglutinin disease.
Benefits of Treatment
Enjaymo offers a targeted treatment approach for adults with cold agglutinin disease by addressing the underlying complement-mediated process responsible for red blood cell destruction.
Potential benefits include reducing hemolysis, improving hemoglobin levels, decreasing the need for blood transfusions, and helping manage symptoms associated with chronic anemia. By limiting destruction of red blood cells, treatment may help improve overall disease control and reduce complications related to ongoing hemolysis.
Clinical studies demonstrated improvements in measures related to anemia and transfusion requirements in eligible patients with CAD. Because individual responses vary, healthcare providers monitor treatment effectiveness through laboratory testing and ongoing clinical evaluation.
Important Safety Information and Side Effects
Enjaymo does not carry an FDA Boxed Warning. However, because the medication affects part of the immune system, important safety considerations should be discussed before treatment begins.
The most commonly reported side effects include respiratory tract infections, viral infections, diarrhea, runny nose, joint pain, high blood pressure, headache, nausea, cough, and fatigue. Most side effects are mild to moderate, although serious complications can occur.
One of the most important risks associated with Enjaymo is an increased susceptibility to serious infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. These infections may become severe, life-threatening, or fatal despite vaccination.
Patients should receive recommended vaccinations against these organisms at least two weeks before starting treatment whenever possible. If treatment must begin sooner, vaccinations should be administered as soon as feasible according to current immunization guidelines. Vaccination reduces risk but does not completely eliminate the possibility of serious infection.
Patients should seek immediate medical attention if they develop symptoms of infection, including fever, chills, persistent cough, severe headache, neck stiffness, confusion, or other concerning symptoms.
Infusion-related reactions may occur during or after treatment. Symptoms can include flushing, shortness of breath, dizziness, fever, chills, and nausea. Patients are monitored during infusions, and treatment may be interrupted or discontinued if severe reactions occur.
Hypersensitivity reactions, including serious allergic reactions, have also been reported. Patients should seek immediate medical care if they experience rash, swelling, difficulty breathing, severe dizziness, or other signs of an allergic reaction.
Because discontinuing Enjaymo may result in recurrence of hemolysis and worsening anemia, patients who stop treatment should be monitored closely. Healthcare providers may evaluate hemoglobin levels, bilirubin, lactate dehydrogenase (LDH), reticulocyte counts, and clinical symptoms following discontinuation.
Patients who are pregnant, planning to become pregnant, or breastfeeding should discuss the potential risks and benefits of treatment with their healthcare provider. Patients should also inform their healthcare team about all medications, supplements, and vaccinations before beginning therapy.
Access to Multiple Medications
Support Beyond Enjaymo
Enrolling with Prescription Hope to access the Enjaymo patient assistance program is often just the beginning.
Many patients require more than one brand-name medication. With our list of hundreds of medications and programs we service, we can often help patients access multiple medications.
No matter how many medications you qualify for, our service rate remains a simple $70.00 per month, per medication. That means no complex pricing structures or hidden fees based on the number of meds.
Why Choose Prescription Hope for Enjaymo Assistance
Patient-Focused Medication Support
For 20 years, Prescription Hope has offered prescription affordability support to Americans who need it most. Our medication access specialists provide advocacy on your behalf throughout the application process.
Simplified Access to Specialty Therapies
Our service rate is a simple $70.00 per month, per medication. You can expect a monthly service rate that never includes add-ons, medication costs, hidden fees, or variable pricing.
Ongoing Prescription Assistance
Our CAD treatment support doesn’t end with applying for your prescription affordability program. We continue to handle all tasks associated with maintaining acceptance status in a patient assistance program. We manage refill scheduling, document updates, yearly renewals, and more.
Nationwide Network
Prescription Hope has developed a network that has come to include hundreds of pharmaceutical manufacturers, tens of thousands of healthcare providers, and hundreds of thousands of patients across America.
Ready to get started with the Enjaymo Patient Assistance Program? Enroll with Prescription Hope to find out how you can save!